Menarini Group and its Stemline Therapeutics subsidiary will present new safety and preliminary efficacy data from the Phase 1b/2 ELEVATE study of elacestrant in combination with capivasertib in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer at the 2026 American Society of Clinical Oncology Annual Meeting. The update places elacestrant, already established as an oral endocrine therapy in ESR1-mutated advanced or metastatic breast cancer, deeper into the combination-treatment debate as oncology developers look for better ways to manage resistance after endocrine therapy and CDK4/6 inhibitor exposure.

Why elacestrant combination data matter as endocrine resistance becomes the central commercial and clinical battleground

The significance of the ELEVATE update is not simply that Menarini Group has another dataset for elacestrant. The more important signal is that the Italian pharmaceutical and diagnostics group is trying to move the asset from a defined monotherapy role toward a broader position as an endocrine therapy backbone in advanced breast cancer. That is a very different commercial and clinical proposition.

In estrogen receptor-positive, HER2-negative metastatic breast cancer, treatment strategy has increasingly shifted from broad endocrine sequencing toward molecularly informed decision-making. ESR1 mutations can reduce sensitivity to aromatase inhibitors, while PI3K pathway alterations, including PIK3CA mutations, can support tumor survival and disease progression. This means many patients do not face a single resistance pathway. They may carry overlapping mechanisms that make one-dimensional treatment strategies less durable.

That is where the elacestrant plus capivasertib combination becomes strategically relevant. Elacestrant targets estrogen receptor signaling, while capivasertib is designed to inhibit AKT in the PI3K/AKT pathway. A regimen that can address both endocrine resistance and PI3K pathway-driven tumor biology could give clinicians another way to think about treatment sequencing, particularly for patients whose disease biology is becoming more complex after prior therapy.

The caution is that the current dataset remains early. A Phase 1b cohort can provide useful signals on tolerability, dose selection, and preliminary activity, but it cannot yet answer whether the regimen will outperform existing standards across a larger and more diverse population. In oncology, promising early response and disease control rates often need to survive the harder test of randomized evidence, mature progression-free survival data, and real-world tolerability outside tightly monitored trial settings.

What the ELEVATE study reveals about Menarini’s broader attempt to build elacestrant into a platform therapy

The ELEVATE study is structured as an umbrella trial evaluating elacestrant with multiple combination partners, including CDK4/6 inhibitors and agents targeting the PI3K/AKT/mTOR pathway. That design matters because Menarini Group is not treating elacestrant as a single-use asset. It is building a clinical-development architecture around the idea that elacestrant could pair with several targeted agents across different resistance patterns.

The capivasertib arm is especially interesting because AKT inhibition has become more relevant in hormone receptor-positive breast cancer as the field searches for ways to extend disease control beyond standard endocrine-based regimens. The reported recommended Phase 2 dose cohort used elacestrant with capivasertib on an intermittent dosing schedule, and preliminary results showed disease control, clinical benefit, and objective responses among response-evaluable patients. The reported objective responses occurring in patients with co-existing ESR1 and PIK3CA mutations make the dataset more biologically interesting, even if the sample size remains small.

That biological signal is commercially useful because breast cancer drug development is increasingly shaped by biomarker-defined subsets. Treatments that can show activity in genetically or pathway-defined populations often have a clearer path to clinical relevance, provided later studies confirm benefit. For Menarini Group, this could support a differentiated positioning strategy for elacestrant combinations rather than forcing the product into a crowded, generic endocrine therapy narrative.

The unresolved question is whether this combination strategy can remain practical. Combination regimens can improve mechanistic coverage, but they can also bring additive toxicity, adherence complexity, higher treatment costs, and greater reimbursement scrutiny. Clinicians may welcome a rational dual-targeting strategy, but only if the benefit is large enough to justify the added treatment burden.

How elacestrant plus capivasertib could influence treatment sequencing in ESR1 and PIK3CA-mutated disease

Treatment sequencing is one of the hardest commercial questions in metastatic breast cancer. Clinicians must decide not only whether a therapy works, but when it works best, after which prior therapies, and in which mutation-defined population. The elacestrant plus capivasertib data speak directly to this sequencing problem because ESR1 and PIK3CA mutations can coexist and may push physicians toward multiple lines of targeted intervention.

A combination that addresses both estrogen receptor signaling and AKT pathway activation could reduce the need to treat one resistance mechanism first and the other later. That is the strategic appeal. If later-stage evidence supports the approach, it could create a stronger rationale for earlier use in selected patients whose tumor biology suggests that sequential single-pathway treatment may be less effective.

The clinical relevance also depends on where the regimen would fit relative to existing endocrine therapy combinations, selective estrogen receptor degraders, PI3K pathway-directed therapies, AKT inhibitors, mTOR inhibitors, chemotherapy, and antibody-drug conjugates. The breast cancer market is not short of treatment options. The challenge is proving that a new combination improves decision-making rather than simply adding another branch to an already crowded treatment tree.

The limitation is that early trial activity in mutation-positive patients does not automatically define a new standard. Regulators and payers will want robust endpoint data, especially progression-free survival, overall response durability, discontinuation rates, and subgroup consistency. If the benefit appears concentrated in a narrow biomarker-defined population, commercial adoption could still be meaningful, but it would require precise testing workflows and clear clinician education.

Why safety and tolerability may matter as much as efficacy in oral breast cancer combinations

The preliminary ELEVATE update indicates that the safety profile of elacestrant plus capivasertib is consistent with the known profiles of the individual targeted therapies and standard endocrine therapy. That is important because metastatic breast cancer is often managed over long periods, and tolerability can strongly influence whether patients remain on therapy long enough to benefit.

Oral oncology combinations carry a practical advantage when they allow patients to avoid infusion-heavy treatment schedules. However, oral regimens also shift more responsibility to adherence, symptom management, dose modifications, and monitoring. In a real-world setting, even manageable adverse events can affect persistence if patients are older, heavily pretreated, or managing multiple comorbidities.

For elacestrant, this is especially relevant because the commercial thesis around endocrine therapy backbones depends on sustained use. A drug that works as part of multiple combinations must be tolerable enough to remain attractive across different partner therapies. If safety remains manageable across CDK4/6, PI3K, AKT, and mTOR-directed combinations, Menarini Group could build a stronger argument for elacestrant as a flexible backbone rather than a niche post-endocrine option.

The watchpoint is whether safety remains consistent as the study moves into larger cohorts and later-stage testing. Smaller Phase 1b datasets can underrepresent less common adverse events, treatment discontinuation patterns, and tolerability differences across patient subgroups. The real test will be whether the regimen can maintain dose intensity without compromising quality of life or forcing frequent interruptions.

What Menarini’s wider elacestrant program suggests about its oncology ambitions beyond metastatic disease

Menarini Group is also advancing elacestrant through several other studies, including combinations with abemaciclib, everolimus, alpelisib, ribociclib, palbociclib, and capecitabine, along with development in early breast cancer. This breadth signals a deliberate attempt to stretch elacestrant across multiple treatment settings and disease stages.

The early breast cancer program is particularly important because success in adjuvant or high-risk settings could materially expand the drug’s relevance. Metastatic breast cancer indications can create strong specialist adoption, but earlier-stage disease can reshape long-term commercial opportunity if the therapy demonstrates meaningful recurrence-risk reduction. That is a much higher bar, however, because early breast cancer trials often require longer follow-up, larger populations, and a very clear benefit-risk profile.

The metastatic combination program is more immediately actionable because it targets a population where unmet need is clearer and treatment escalation is more common. Yet the early breast cancer ambition reveals the bigger strategic goal. Menarini Group appears to be positioning elacestrant not merely as a later-line endocrine option, but as a molecule that could compete across the endocrine resistance continuum.

The risk is program complexity. Running multiple combination and disease-stage studies requires capital, clinical execution discipline, partner coordination, and careful prioritization. A broad pipeline can create optionality, but it can also dilute focus if the strongest signals are not rapidly identified and advanced.

What clinicians, regulators, and industry observers will watch after ASCO 2026

The most important next question is whether the preliminary efficacy signals from elacestrant plus capivasertib translate into stronger and more mature Phase 2 data. Disease control rate, clinical benefit rate, objective response rate, and early progression-free survival signals are helpful, but oncology practice changes when datasets mature and comparisons become clearer.

Clinicians will likely focus on whether the combination provides meaningful benefit in patients with co-existing ESR1 and PIK3CA mutations, because that is where the mechanistic rationale appears most compelling. If the benefit is consistent in this subgroup, the regimen could eventually support a more biomarker-driven treatment approach. If the signal weakens or proves inconsistent, the combination may remain scientifically interesting but commercially limited.

Regulators will focus on trial design, endpoint maturity, population definition, safety characterization, and the adequacy of future confirmatory evidence. Payers will focus on whether the combination improves outcomes enough to justify the cost and complexity of dual targeted therapy. Pharmaceutical competitors will watch whether Menarini Group can turn elacestrant into a repeatable combination platform before rival endocrine agents and pathway inhibitors crowd the same space.

For Menarini Group and Stemline Therapeutics, the ASCO 2026 update is best read as a strategic marker rather than a definitive inflection point. The data support the logic of targeting multiple resistance pathways in ER-positive, HER2-negative metastatic breast cancer, particularly where ESR1 and PIK3CA mutations coexist. The harder work begins after the conference spotlight moves on: validating the signal, clarifying the patient population, and proving that elacestrant combinations can deliver enough durable benefit to change how clinicians sequence therapy.

  ASCO 2026, capivasertib, Elacestrant, ELEVATE study, endocrine therapy, ER-positive breast cancer, ESR1 mutation, HER2-negative breast cancer, Menarini Group, metastatic breast cancer, PIK3CA mutation, Stemline Therapeutics